/HLN
Haleon plc
HLN • NYSEHLN • NYSE • Healthcare
$10.47-1.32%-0.14
$10.47-1.32%(-0.14)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
35Bearish
Risk
100Low Risk
Momentum
57Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
64.8%▲2.9pp
Revenue after COGS
Operating
22.4%▲2.8pp
After operating expenses
Net
15.1%▲2.3pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
20.6
Price vs earnings
EV/EBITDA
14.7
Enterprise value
FCF Yield
5.9%
Cash generation
Earnings Yield
4.8%
Inverse of P/E
Capital Efficiency
7
GoAI Quality ScoreWeak
ROEReturn on Equity
9.9%Fair
ROAReturn on Assets
5.0%Strong
ROICReturn on Invested Capital
6.6%Fair
Financial Health
Current RatioWeak
0.92
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
2.62x
Debt repayment capacity (<3x)
Income QualityStrong
1.40
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $10.79B | $11.23B | $11.30B | $10.86B | $9.54B |
| Gross Profit | $6.99B | $6.95B | $6.96B | $6.58B | $5.95B |
| Gross Margin | 64.8% | 61.9% | 61.6% | 60.6% | 62.3% |
| Operating Income | $2.42B | $2.21B | $2.00B | $1.82B | $1.64B |
| Net Income | $1.63B | $1.44B | $1.05B | $1.06B | $1.39B |
| Net Margin | 15.1% | 12.8% | 9.3% | 9.8% | 14.6% |
| EPS | $0.36 | $0.32 | $0.24 | $0.24 | $0.30 |
Average Price Target
$10.20▼ 2.6% Downside
Past 12 Months
12 Month Forecast
Based on 8 Wall Street analysts offering 12 month price targets for Haleon plc, the average price target is $10.20, with a high forecast of $10.20 and a low forecast of $10.20. The average price target represents a 2.6% decrease from the current price of $10.47.
Highest
$10.20
Average
$10.20
Lowest
$10.20
Rating Distribution
Strong Buy
0
0%
Buy
3
75%
Hold
1
25%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays▲ Upgrade
Equal Weight→Overweight
2026-01-23Barclays▼ Downgrade
Overweight→Equal Weight
2025-09-16Morgan Stanley● Maintain
Overweight
2024-09-20Argus Research● Maintain
Buy
2024-03-26Argus Research▲ Upgrade
Hold→Buy
2023-04-06Argus Research▲ Upgrade
Hold→Buy
2023-04-05Argus Research● Maintain
Hold
2022-09-28Deutsche Bank● Maintain
Hold
2022-07-29Earnings History & Surprises
BEAT RATE
30%
Last 10 quarters
AVG SURPRISE
-28.2%
EPS vs Estimate
BEATS / MISSES
3/7
Last 10 quarters
LATEST EPS
$0.26
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+2.3%
$0.26 vs $0.25
Q4 '25
-42.8%
$0.14 vs $0.24
Q3 '25
-67.3%
$0.08 vs $0.24
Q1 '25
-99.8%
$0.05 vs $25.25
Q4 '24
+27.3%
$0.14 vs $0.11
Q2 '24
+9.1%
$0.12 vs $0.11
Q1 '24
-36.3%
$6.54 vs $10.27
Q3 '23
-63.5%
$0.08 vs $0.22
Q1 '23
-9.7%
$0.21 vs $0.23
Q3 '22
-1.6%
$0.22 vs $0.22
Q4 '21
No data
Q2 '21
No data
No investor questions available.
Latest News
No news available